The investigation targets the proposed sale of Bowhead Specialty Holdings to American Family Mutual Insurance Company for $34.00 per share, and the acquisition of Atkore by Prysmian S.p.A. at $95.00 per share. Additionally, the firm is examining the stock-for-stock merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals, which values each Supernus share at 1.5401 shares of Indivior.

Halper Sadeh attorneys are assessing whether these deals include restrictive terms that stifle superior competing offers or provide insiders with financial advantages not extended to the broader shareholder base. The firm, based at One World Trade Center in New York, operates on a contingent fee basis for these matters, seeking either increased consideration for investors or enhanced disclosures regarding the terms of the sales.